Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec 1;47(11):1479-85.
doi: 10.1086/593104.

Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program

Christopher J Hoffmann  1 , Salome Charalambous, Desmond J Martin, Craig Innes, Gavin J Churchyard, Richard E Chaisson, Alison D Grant, Katherine L Fielding, Chloe L Thio
Affiliations

Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program

Christopher J Hoffmann et al. Clin Infect Dis. .

Abstract

Background: Coinfection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is common in Africa; however, the impact of HBV infection on the outcomes of antiretroviral therapy programs is unclear. We evaluated the impact of chronic hepatitis B on HIV virologic response, changes in CD4 cell count, hepatotoxicity, and mortality among Africans receiving highly active antiretroviral therapy (HAART).

Methods: We conducted a retrospective cohort study involving a workplace HAART program in South Africa. Participants received HAART according to a protocol and were followed up for up to 72 weeks. On the basis of pre-HAART serum assays, patients were classified as being hepatitis B surface antigen (HBsAg) negative, HBsAg positive with a low HBV DNA level (</= 1 x 10(4) copies/mL), and HBsAg positive with a high HBV DNA level (> 1 x 10(4) copies/mL). The relationships between HBV status and HIV RNA suppression, change in CD4 cell count, mortality, and hepatotoxicity were assessed with use of regression techniques.

Results: Five hundred thirty-seven individuals fulfilled the inclusion criteria; 431 (80.3%) of these patients were HBsAg negative, 60 (11.2%) were HBsAg positive with a low HBV DNA level, and 46 (8.6%) were HBsAg positive with a high HBV DNA level. All groups had similar rates of HIV RNA suppression (P = .61), CD4 cell count increases (P =.75), and mortality (17 total deaths; P=.11) for up to 72 weeks after the initiation of HAART. Baseline transaminase levels were highest in the group with high HBV DNA levels (P=.004). Hepatotoxicity was similar between the HBsAg-negative group and the group with low HBV DNA levels but was higher in the group with high HBV DNA levels (incidence rate ratio, 4.4).

Conclusions: We revealed that HBV status does not affect HIV RNA suppression, CD4 cell count response, or mortality during the first 72 weeks of HAART in an African setting. The risk of HBV-associated hepatotoxicity, however, is associated with the baseline HBV DNA level.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: no conflicts.

Figures

Figure 1
Figure 1
Proportion of patients who achieved HIV RNA suppression (HIV RNA level, <400 copies/mL) at 6, 24, 48, and 72 weeks after initiation of HAART, by hepatitis B virus (HBV) infection group. HBsAg, hepatitis B surface antigen.
Figure 2
Figure 2
Median change in CD4 cell count at 6, 24, 48, and 72 weeks after the initiation of HAART, by hepatitis B virus (HBV) infection group. HBsAg, hepatitis B surface antigen; IQR, interquartile range.
Figure 3
Figure 3
Kaplan-Meier graph showing the proportion of patients who experienced episodes of hepatotoxicity, by hepatitis B virus (HBV) infection group. ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen.
See this image and copyright information in PMC

Comment in

References

    1. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7:402–9. - PubMed
    1. Wit FWM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31. - PubMed
    1. Thio CL, Seaberg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) Lancet. 2002;360:1921–6. - PubMed
    1. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80. - PubMed
    1. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals. Drug Safety. 2005;28:53–66. - PubMed

Publication types

MeSH terms